France
• YES, 20% price reduction at first generic entry and further 12.5% reduction after 18 months  
Germany
• YES, 10% mandatory discount on off-patent originals and generics plus 6% additional discount on non-reference priced off-patent originals and generics (vs. 7% mandatory discount on non-reference priced patented drugs)
 

Spain
• YES, price of the first generic must be 40% below the price of off-patent original; original product enters reference price system and has to reduce its price to the level of generic price, otherwise it is excluded from reimbursement  
Italy
• YES, price of the first generic must be 30-75% below the price of off-patent original and reimbursement price of the original drug decreases to the reference price  
UK
• NO, free pricing but there is a strong competition due to very low generics' prices; majority of generics are assigned to category M of Part VIIIA of the Drug Tariff list which means that reimbursement prices for these products are calculated based on volume-weighted actual average selling prices; most prescriptions are made by an international nonproprietary name resulting in effective generic substitution and quick price erosion of off-patent originals Interestingly, these 5 drugs were biological products (Herceptin®, Remicade®, Rebif®, Mabthera®, antilymphocyte globulins), less exposed to follow-on competition than small molecules.
• In order to protect the price and counterbalance additional R&D investments new indications are more likely to be pursued during early to mid-stage of products life-cycle rather than for MPs, as there is an incentive to do it. If a new indication, which brings a significant clinical benefit in comparison with existing therapies, is obtained within 8 years after the first marketing approval the manufacturer gains one additional year of market protection [3] .
CASE STUDY: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
• SLE is a chronic autoimmune disease with a heterogeneous clinical presentation. The prevalence of SLE is estimated at 12.5-78.5 cases per 100,000 population in Europe and the USA [4] .
• A wide range of drugs for the treatment of SLE are used off-label. Most of them are MPs, for which no regulatory process has been conducted in this specific indication. However, in 2011 belimumab (Benlysta®, GSK) -a fully-humanised monoclonal antibody -became the first drug for 50 years to be licensed in SLE (Table 2 ).
• In Europe an annual cost of treatment with old drugs ranges from approximately €70 to €2,500 (based on ex-factory prices), i.e.: an annual cost of hydroxychloroquine is €74, oral prednisolone €119, azathioprine from €83 to €250, cyclophosphamide from €266 to €532 and injectable hydrocortisone from €512 to €2,559 [5] .
• In contrast, an annual cost of belimumab (15 administrations a year) can reach €14,680, which is 6-times more as compared with the highest possible dose of injectable hydrocortisone and nearly 200-times more as compared with hydroxychloroquine [5] .
DISCUSSION
• Introduction of European level incentives for development of orphan (since 1999) and pediatric medicines (since 2007) resulted in an increased number of new approvals benefiting a range of previously disadvantaged patient groups.
• Similarly, an introduction of incentives stimulating development of new indications for MPs can be a win-win solution for patients and payers. It offers an alternative to off-label use of drugs, which is estimated to account for 15-20% (6) of all prescriptions in general (data for France) and 50%, or even more, in oncology [7] . Off-label use may pose safety risk, if side-effects or interactions profile is not well documented for off-label indication. It also generates risks of additional costs without proof of efficacy and exposes healthcare providers to liability. Moreover, off-label prescription is often limited to patients treated by KOLs. Therefore, new indications with MPs could allow to reduce risks and lack of equity associated with off-label use.
• Development of MPs offers, in addition, an alternative to lengthy and expensive development of new therapies. It has been estimated that de novo drug discovery and development lasts from 10 to 17 years and is associated with <10% probability of success while in case of repositioned drugs the overall process may be shortened to even 3 to 12 years [8] . As safety accounts for almost 30% [9] of drug failures in clinical trials, MPs, for which large amount of valuable real life data are available, should be considered as an interesting option.
• In the current environment there are no incentives to invest in MPs, while this can be innovative and cost-effective. New innovations are needed and should be rewarded, but to breath new life into existing products is also innovative and may in addition help reducing pressures on healthcare budgets, hence improving affordability across healthcare systems. Table 2 . Drugs used in the treatment of SLE Table 3 . New drugs in development for SLE
